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 Abstract: Collectively, cell penetrating peptide (CPP) vectors and intrinsically active 
bioportides possess tremendous potential for drug delivery applications and the discrete 
modulation of intracellular targets including the sites of protein-protein interactions (PPIs). 
Such sequences are usually relatively short (<25 AA), polycationic in nature and able to 
access the various intracellular compartments of eukaryotic cells without detrimental 
influences upon cellular biology. The high-throughput platform for bioportide discovery 
described herein exploits the discovery that many human proteins are an abundant source of 
potential CPP sequences which are reliably predicted using QSAR algorithms or other 
methods. Subsequently, microwave-enhanced solid phase peptides synthesis provides a high-
throughput source of novel proteomimetic CPPs for screening purposes. By focussing upon 
cationic helical domains, often located within the molecular interfaces that facilitate PPIs, 
bioportides which act by a dominant-negative mechanism at such sites can be reliably 
identified within small number libraries of CPPs.  Protocols that employ fluorescent peptides, 
routinely prepared by N-terminal acylation with carboxytetramethylrhodamine (TAMRA), 
further enable both the quantification of cellular uptake kinetics and the identification of 
specific site(s) of intracellular accretion.  Chemical modifications of linear peptides, 
including strategies to promote and stabilise helicity, are compatible with  the synthesis of 
second-generation bioportides with improved drug-like properties to further exploit the 
inherent selectivity of biologics. 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
The eukaryotic plasma membrane represents a significant obstacle for the development of 
both drugs and biological research tools that require access to intracellular target sites to 
influence cellular biology. Cell penetrating peptides (CPPs) are a versatile technology that 
can negate the pharmacokinetic challenges of lipid barriers to afford the efficient delivery of 
bioactive cargoes (Mae and Langel 2006, Milletti 2012).  More recently, a novel genre of 
CPP, distinct from conventionally inert vectors, has been described (Howl and Jones 2008, 
Howl et al. 2012) which combines the dual properties of cellular penetration and biological 
activity. Termed bioportides (Howl and Jones 2008, Howl et al. 2012), these proteomimetic 
CPPs often derive from cationic helical domains of key signalling proteins and commonly act 
as biological modulators of protein-protein interactions (PPIs; Howl and Jones 2008, Howl et 
al. 2012, Howl et al. 2015, Lukanowska et al. 2013). 
 Collectively, CPP and bioportide technologies possess tremendous potential to 
modulate intracellular protein function and so expand the known repertoire of drug targets. 
An overwhelming majority of recently developed CPPs are relatively short (12-25 AA) 
sequences in which both lysine and, perhaps more commonly, arginine contribute to a net 
positive charge. Some of these, including the common delivery vectors Tat 
(GRKKRRQRRRPPQ; Vivés et al. 1997) and Penetratin  (RQIKIWFQNRRMKWKK; 
Derossi et al. 1994), derive from known helical domains of transcription factors which 
facilitate membrane translocation. Other CPP sequences, including the Transportans  
(Soomets et al. 2000) can be successfully modelled as an amphipathic helix. Polyarginine-
containing CPP sequences have also been identified as cryptic fragments of the primary 
sequences of other structurally-diverse human proteins (Futaki et al. 2001). Thus, it is 
tempting to speculate that one or multiple polycationic sequences may enable functionally-
diverse supercharged proteins (Cronican et al. 2011) to traverse biological membranes and so 
fulfil their biological role(s).   
 Robust methodologies, employing quantitative structure -activity relationship (QSAR) 
models (Hällbrink et al. 2005), to accurately predict CPPs within vertebrate proteins are 
described herein. Protocols for the high-throughput synthesis of polycationic peptides using 
microwave-enhanced solid-phase methodologies are also reported. As developed to confirm 
and quantify effective cellular penetration (Howl et al. 2012, Jones et al. 2010, Jones et al. 
2016), we also describe both qualitative and quantitative methodologies that permit an 
assessment of translocation efficacies and determination of the intracellular sites of accretion 
of both CPPS and bioportides. Finally, we suggest a variety of structural modifications, 
compatible with microwave-enhanced solid phase synthesis, which may improve both the 
pharmacokinetic and pharmacodynamic properties of bioportides. Collectively, these 
sequential methodologies permit the positive identification of bioportides that possess some 
of the desirable properties associated with small molecular weight drugs whilst retaining the 
exquisite selectivity and potency of macromolecular biologics (Craik et al. 2013).  
 
Experimental 
 
Selection of Cryptic Peptide Sequences 
 
The initial step towards the synthesis of linear proteomimetic CPPs is to identify cationic 
stretches within the primary sequence of entire proteins or those with a more restricted 
distribution within protein domains with a known regulatory function.  As first described by 
Futaki and co-workers (2001), many arginine-rich sequences, 12-28 AA in length and 
identified within both RNA- and DNA-binding proteins, proved to be efficient CPPs.  By 
analogy with the Tat peptide (Vivés et al. 1997), these observations indicate the relative ease 
by which it is possible to identify new CPP sequences and suggest that polybasic proteins 
might utilise common internalisation mechanisms to achieve a cellular response (Cronican et 
al. 2011), 
 QSAR analyses provide a more scientifically rigorous approach to the identification 
of novel proteomimetic CPPs. The training of a QSAR prediction algorithm with known CPP 
sequences supports the comparison of the bulk properties of amino acids within primary 
sequences. Two of four Q variable scores are particularly important descriptors of CPPs and 
can be used to reliably predict others that are cryptic fragments of whole proteins.  For this 
purpose, we have often utilised the platform developed by Langel’s team in Stockholm 
(Hällbrink et al. 2005) that in our experience is particularly reliable for the prediction of new 
CPPs that are ≥ 12 amino acids in length (Fig. 1A).  Publicly-accessible sites that provide a 
similar readout using mathematical prediction are more recently available and include 
CellPPD: Designing of Cell Penetrating Peptides (www.imtech.res.in/raghava/cellppd/; 
Gautam et al. 2015)). It would be particularly informative to compare the outputs from 
different predictive platforms with the anticipation of identifying some consensus. 
 It is common that QSAR analyses (Hällbrink et al. 2005) identify many overlapping 
CPPs within vertebrate proteins. For example, human Cytochrome  c was predicted to contain 
~25 polycationic CPPs (Jones et al. 2010). Within the primary sequence of larger proteins 
such as the Leucine Rich Repeat Kinase 2 the total number of predicted CPPs exceeds 2,500. 
Moreover, we commonly observed that QSAR prediction illuminated CPPs within cationic 
helices including those that reside at the sites of protein-protein interactions. A striking 
example was provided by our studies with Cytochrome c in which all predicted CPPs derived 
from spatially contiguous helical domains at the N- and C- termini of the protein (Howl et al. 
2010). Thus, in our search for rhegnylogically-organised bioportides (Howl and Jones 2008, 
Howl et al. 2012, Howl et al. 2015, Lukanowska et al. 2013), we have focussed efforts upon 
those predicted CPPs which derive from well-defined protein structures, particularly α-
helices. 
 
Microwave Enhanced Solid Phase Peptide Synthesis 
 
It is perfectly feasible to synthesise CPPs and bioportides at room temperature in simple glass 
reaction vessels employing standard protocols for activation and deprotection from 9-
Fluorenylmethyloxycarbonyl (Fmoc)-protected AAs (Chan and White, 1999).  We now 
utilise such methods mostly for the amino-terminal acylation of peptides on resin with 
fluorophores and instead prefer to employ microwave-enhanced peptide chemistry. Synthesis 
at higher temperatures, 75 or 90oC, reduces cycle times and often improves both the purity 
and yield of the desired product. Detailed protocols for the semi-automated synthesis of 
peptides with a Discover SPS Microwave Peptide Synthesizer are reported elsewhere (Howl 
and Jones 2015a). Using this system, O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HCTU) is a reliable condensation reagent and 
most coupling reactions were performed at 75oC for 10 mins.   
 Higher throughput using a CEM Liberty Blue Synthesizer equipped with UV analyser 
is now our method of choice for the routine synthesis of polycationic CPPs and bioportides in 
Dimethylformamide (DMF). To negate a negatively charged carboxyl terminal, which could 
be detrimental to cellular penetrations, and to improve stability against proteases, we 
commonly synthesize CPPs and bioportides on Rink Amide 4-Methylbenzhydrylaamine 
(MBHA) cross-linked polystyrene resins (Novabiochem) to generate peptide amides. Whilst 
compatible with HCTU chemistry, when using this synthetic platform we routinely employ a 
coupling methodology developed by CEM to facilitate synthesis at 90oC with enhanced 
coupling efficiency and reduced side reactions. For this purpose, N,N'-
Diisopropylcarbodiimide (DIC) is used as the condensation reagent with the additive Ethyl 2-
cyano-2-(hydroxyimino)acetate (Oxyma; Subirs-Funosas et al. 2009) plus a lower 
concentration  of N,N-Diisopropylyethylamine (DIPEA).  Syntheses on a 0.1 mmole scale are 
performed using a 5-fold molar excess of AA/DIC/Oyxma with 0.1 molar equivalent of 
DIPEA in a final volume of 4 ml. Microwave power is routinely applied in three steps to 
rapidly heat reagents in the 30 ml reaction vessel and subsequently more accurately maintain 
the final temperature for the desired period. For example, a standard coupling of most AAs is 
achieved (power/maximum temperature/time) by 100 W/80oC/20 s, 55 W/86oC 10 s, 20 W, 
90oC/120 s to minimise temperature fluctuations around the holding temperature of 90oC.  
Special coupling cycles are used for Arg, double coupling 30 W/75oC/300 s, and Cys/His, 
single coupling 30 W/50oC/600 s. These protocols reduce δ-lactam formation of arginine and 
racemisation of Cys/His respectively. A standard deprotection cycle with 20% (v/v) 
Piperidine in DMF is reduced to 60 s at 90oC and is routinely monitored by determining the 
UV absorption at 301 nm of Dibenzofulvene-piperidine adducts (Fig. 2).  
 Amino-terminal acylation of CPPs and bioportides is a convenient route to the 
production of fluorescent peptides for applications such as confocal microscopy (Fig. 1B). 
We favour the single isomer 6-Carboxytetramethylrhodamine for applications with 
eukaryotic cell systems as this chromophore provides excellent photo-stability and pH-
insensitive fluorescence (Jones et al. 2016). All peptides described herein were purified to 
apparent homogeneity by reverse phase HPLC and analysed by mass spectroscopy (Fig. 1C) 
to confirm their mass (Howl et al. 2012, Jones et al. 2016). 
 
 
 
Live Cell Confocal Microscopy  
 
To avoid the potential for fixation artefacts that could promote a redistribution of fluorescent 
peptides, we routinely utilise living cell monolayers to assess the intracellular uptake of 
TAMRA-conjugated CPPs and bioportides (Howl et al. 2012, Jones et al. 2016). Cells are 
cultured in 35 mm glass base dishes and incubated with fluorescent peptides whilst 
maintaining standard culture conditions of 37oC and a humidified atmosphere of 5% CO2. As 
a rule, a final assay concentration of 5 µM peptide is used in initial experiments to provide 
optimal signal intensity whilst avoiding possible non-specific membrane perturbations 
associated with high concentrations of CPP (Howl and Jones 2015a). Immediately prior to 
observation, cells are washed gently with phenol red free medium (8x) and subsequently 
analysed with a Carl Zeiss LSM510Meta confocal microscope equipped with a live cell 
imaging chamber. Other fluorescent dyes providing a single carboxylic acid, including 
fluorescein, are also readily conjugated to CPPs and bioportides using conventional peptide 
chemistry. A variety of fluorescent markers can be employed (Jones et a. 2010, Jones ert al, 
2016) to confirm the intracellular distribution of CPPs and bioportides in living cells (Fig. 
1D). 
 
Quantitative Assessment of Cellular Internalisation  
 
Fluorescent CPPs and bioportides are convenient probes with which to quantify cellular 
internalisation (Fig. 1D). In many of our studies (Jones et al. 2010, Jones et al. 2016),  we 
have employed U373MG astrocytoma cells routinely maintained in a humidified atmosphere 
of 5% CO2 at 37oC in DMEM supplemented with L-glutamine (0.1 mg/ml), 10% (wt/vol) 
fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin (100 μg/ml). Unlike our 
confocal analyses of cellular penetration, this method permits the incorporation of a 
trypsinisation step so as to remove non-internalised cell surface-associated peptide.  For this 
purpose, U373MG cells are transferred to 6-well plates and grown to 80% confluence. Cells 
are washed and maintained in phenol red-free DMEM and subsequently treated with 
TAMRA-conjugated peptides at a final concentration of 5 µM for 1 hour in culture 
conditions as above. Cells were then washed four times, detached with 300 µl of 1 % (w/v) 
trypsin (without phenol red) at 37 °C, collected by centrifugation and lysed in 300 µl 0.1 M 
NaOH for two hours on ice. 250 µl of each sample cell lysate are transferred to a black 96-
well plate, and analysed using a ThermoFischer Scientific Fluoroskan Ascent FL 
flurorescence spectrophotometer (λAbs 544nm/λEm 590 nm), (Fig. 1D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and Discussion 
 
Many bioportides derive from known cationic domains of signalling proteins and the 
amphipathic helix is a common structural motif that may be essential for both cellular entry 
and bioactivities. Thus, the focus of our efforts to develop bioportides which mimic cationic 
helices within human proteins affords advantages that are both pharmacokinetic and 
pharmacodynamic in nature. Key to this strategy is the knowledge that cationic residues, 
predominantly Arg, play a common role in the enabling of CPPs to enter cells and the 
subsequent modulation of intracellular protein function (Lukanowska et al. (2013); Howl and 
Jones, 2015b).  After binding to the surface of cells, CPPs and bioportides access the cellular 
interior by a variety of mechanisms that may include a combination of both direct 
translocation and various energy-dependent endocytotic processes (Langel, 2007). Following 
internalisation, possibly in a helical conformation, bioportides commonly exhibit site-specific 
accretion that may enhance or reflect their capacity to modulate the activity of proteins 
preferentially located within defined intracellular loci (Futaki et al. 2001, Lukanowska et al. 
2013).  Polycationic α-helices are a quantitatively dominant secondary structure within the 
extended surfaces that constitute the protein-protein interfaces (PPIs) between 
therapeutically-relevant proteins (Jochim and Arora, 2009).  Moreover, within PPIs Arg is 
commonly enriched (Crowley and Golovin, 2005). Since PPIs are ubiquitous modulators of 
all major signalling pathways that often utilise common promiscuous domains (Pawson and 
Nash, 2000) it is not surprising that aberrant PPI function is a causative factor of many 
human disease states (Vidal et al. 2011).  Hence, there is tremendous scope to develop 
proteomimetic bioportides and the platform described herein is fully compatible with 
synthesis of larger libraries of potential bioportides that could accelerate the drug discovery 
process (Derda 2015). 
 Many bioportides most likely mimic cationic helices within PPI interfaces to achieve 
their biological functions through a predominant dominant-negative mechanism (Kiosses et 
al. 2002, Howl and Jones 2015b). For example, Harada and co-workers (2010) employed the 
cell permeable undecaarginine (Arg11) to deliver a peptidomimetic fragment of the zinc 
finger 224 (ZNF224) interacting domain of human DEP containing 1 protein (DEPDC1611-
628). This sychnologic bioportide (Howl et al. 2008, Lukanowska et al. 2013, Howl and 
Jones 2015b) aptly named DEPDC1-ZNF224, inhibited the interaction of DEPDC1 and 
ZNF244 to trigger transcriptional activation of the A20 zinc finger protein leading to growth 
repression of bladder cancer cells (Harada et al. 2010),  
 It is apparent that folded sub-domains enable proteins to interact in a temporal and 
spatial fashion with their cognate binding partners (Ghoorah et al. 2015). The stabilisation of 
peptides into a defined α-helical conformation can confer distinct pharmacodynamic and 
pharmacokinetic advantages; so many strategies have been developed to achieve this 
synthetic goal (Fig. 3).  For example, α,α-dialkylamino acids such as α-Aminoisobutyric acid 
(Aib) can be incorporated into peptides to increase the propensity for helix formation (Howl 
and Jones 2015b). We commonly substitute Aib for Ala when seeking to employ this simple 
modification. Disulphide bonds, lactam- and metal-mediated bridges, plus a variety of other 
covalent bonds, are also commonly employed to introduce relatively flexible or rigid 
crosslinks that stabilise a helical peptide conformation (Henchey et al. 2008). The 
engineering of bioportides with more drug-like properties may be one of the key challenges 
for many clinical applications. As indicated (Fig. 3), complementary strategies may be 
utilised to improve proteolytic stability, membrane translocation and site-directed 
intracellular target-site affinity. For example, Aileron Therapeutics has recently reported 
(Chang et al. 2013) the development of a stapled α-helical peptide, ATSP-7041, that is a dual 
inhibitor of the Murine double minute (MDM) family members MDM2 and MDMX. Of a 
more unconventional nature (Fig. 3), the design of bivalent analogues of both linear and 
helical bioportides could display enhanced affinity for their intracellular therapeutic target 
(Schiller, 2010). 
 
Conclusions 
 
The presented high-throughput methodologies for the generation of proteomimetic CPPs and 
bioportides provide a unique platform which traverses the scientific disciplines of chemistry 
and biology - from identification and synthesis, to the determination of intracellular fate and, 
finally, the discrete modulation of intracellular processes. Whilst peptide therapeutics have 
been somewhat neglected by the pharmaceutical industry, largely owing to their susceptibility 
to premature proteolysis in vivo, a wealth of stabilisation strategies are now emerging which 
render peptides more pharmacokinetically and yet more pharmacodynamically favourable.  
Such strategies, applicable to both CPPS and bioportides, include modifications which are 
compatible with the formation and stabilisation of cationic α-helices, our favoured locus for 
the therapeutic targeting of PPIs. We trust that our description of this discovery platform will 
encourage others to utilise this emerging technology and to address the development of 
second-generation bioportides that are chemically modified and stabilised linear peptides. 
Such developments will also exploit the unparalleled target specificity and affinity afforded 
by larger macromolecules (Craik et al. 2013) to offer significant promise for the next 
generation of intracellular peptide therapeutics. 
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FIGURE LEGENDS 
 
Fig. 1.  A high-throughput synthetic platform for the discovery of CPPs and bioportides.  A) 
QSAR analyses can reliably identify CPP sequences within many human proteins or selected 
domains (Hällbrink et al. 2005, Howl et al. 2012). The algorithm developed in Stockholm 
provides a numerical indication of CPP probability that rises from possible (1), to probable 
(2) and highly probable (3). This figure indicates that nosangiotide (H-
RKKTFKEVANAVKISA-NH2), a potent anti-angiogenic bioportide (Howl et al. 2012) was 
predicted to be a “highly probable” CPP.   
B) Microwave-enhanced peptide synthesis provides a convenient and reliable route towards 
the synthesis of de novo CPPs and bioportides. The average time required for the synthesis of 
a polycationic tetradecapeptide, such as H-INLKKLAKL(Aib)KKIS-NH2, a derivative of the 
mitochondriotoxic bioportide mitoparan  (Jones et al. 2008;  Fig. 2B (ii)), is reduced from 
several days using manual synthesis to just two hours once the CEM instrument is loaded 
with reagents. A fraction, usually ~0.025 mmole, of the synthesised peptides undergo N-
terminal acylation with TAMRA to provide fluorescent probes for both quantitative and 
qualitative cellular uptake analysis.   
C) Since we tend to sacrifice yield for purity, the HPLC purification of peptides is now a 
rate-limiting step in this high-throughput scheme. We routinely use semi-preparative scale 
methodologies with 4.5 -5.5 mlmin-1 flow rates employing a 250 mm length x 10 mm 
diameter  C18 reverse phase column optimised for the separation of peptides in the range of 
10 -20 AA. The requirements of multiple runs, usually 5or 6, to purify the entire output from 
a 0.1 mmole synthesis at least allows for occasional mistakes to be made.  
D) Both quantitative and qualitative methods are routinely employed to establish cellular 
uptake of TAMRA-labelled bioportides. Fluorescence spectroscopy permits the 
quantification of cellular penetration. An additional trypsinisation step is essential to remove 
any cell surface-associated peptide. To complement these quantitative data, real-time live 
confocal cell imaging analyses are used to determine the precise intracellular distribution of 
TAMRA-labelled bioportides. Cellular fixation is ill-advised owing to artefactual 
redistribution of the bioportide. Fluorescent labelling of organelles or proteins further enables 
quantitative co-localisation analysis which measures the degree of bioportide accretion within 
subcellular structures (Jones et al. 2010). The confocal image depicts TAMRA-Cyt c77-101 
accumulation within the endoplasmic reticulum (Jones et al. 2010) labelled with ER Tracker 
Green FM (Molecular Probes). 
 
 
Fig 2. Semi-quantitative analysis of Fmoc removal is a convenient quality control assessment 
of automated microwave-enhanced peptide synthesis.  
A) Piperidine is commonly utilised to afford the removal of the N-α-Fmoc groups to liberate 
a free amine and the Dibenzofulvene-piperidine adduct (DBF-pip). The absorbance of DBF-
pip at 301 nm is distinct from that of other reagents and so provides a semi-quantitative 
assessment of both Fmoc-removal and coupling efficiency.  
Bi) The successful synthesis of the hexadecapeptide H-RKFPSKKHMQRHIRSH-NH2, 
which was subsequently purified in high yield. This is a cationic sequence located within the 
Ovo transcription factor of the planarian Schmidtea mediterrane (Ovo236-249; Mével-Ninio et 
al. 1991) with an Arg-Lys N-terminal chimeric extension. 
Bii) The attempted synthesis of the tetradecapeptide H-SIKK(Aib)LKALKKLNI-NH2, where 
Aib = α-aminoisobutyric acid, a CPP sequence with potential antimicrobial activities. This 
synthetic process clearly failed and attempts to purify the required sequence proved 
unsuccessful. Double coupling the final three amino acids solved this synthetic problem to 
enable purification of the desired product in high yield. As shown in both bottom panels, it is 
noteworthy that we often observe that a reduced amount of Fmoc is liberated by the first 
deprotection of the resin. We interpret this observation as indicative that not every linker 
attached to the solid phase resin is chemically protected. 
 
Fig. 3. Strategies for the synthesis of stabilised bioportides. In addition to the chemical 
variation of peptide termini and the substitution of unnatural or D amino acids (Howl and 
Jones 2015b), rational synthetic modifications could convert promising functional leads into 
more stable homologues.  
A) Detailed protocols for the introduction of a chemical staple using olefin metathesis are 
available (Kim et al. 2011) though a variety of complementary strategies can also be 
employed to stabilise peptides in a helical formation (Henchey at al. 2008). 
B) Cyclisation of linear peptides in monomeric or dimeric form will almost certainly improve 
oral bioavailability (Wang and Craik, 2016.  Furthermore, bivalent and cyclic bioportides are 
likely to possess higher potencies than their monomeric precursors (Keissling et al. 2000, 
Schiller 2010, Kim et al. 2011, Wang and Craik, 2016). 
C) The dimerisation of stabilised helical monomers could combine the intrinsic stability of 
cyclic peptides with the pharmacodynamic advantages resulting from both enhanced helicity 
and bivalency. The synthesis of cyclic structurally-constrained peptides will not be routine, 
though the preparation of double-stapled helical peptides is compatible with Fmoc-based 
peptide chemistry (Walensky and Bird, 2014), 
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